+Search query
-Structure paper
| Title | Unraveling the molecular mechanism of BNC105, a phase II clinical trial vascular disrupting agent, provides insights into drug design. |
|---|---|
| Journal, issue, pages | Biochem. Biophys. Res. Commun., Year 2020 |
| Publish date | Aug 15, 2019 (structure data deposition date) |
Authors | Wang, T. / Wu, C. / Wang, C. / Zhang, G. / Arnst, K.E. / Yao, Y. / Zhang, Z. / Wang, Y. / Pu, D. / Li, W. |
External links | Biochem. Biophys. Res. Commun. / PubMed:32085900 |
| Methods | X-ray diffraction |
| Resolution | 2.74524106157 Å |
| Structure data | ![]() PDB-6kpp: |
| Chemicals | ![]() ChemComp-GTP: ![]() ChemComp-MG: ![]() ChemComp-CA: ![]() ChemComp-DO6: ![]() ChemComp-GDP: ![]() ChemComp-MES: ![]() ChemComp-GOL: ![]() ChemComp-HOH: |
| Source |
|
Keywords | ANTITUMOR PROTEIN / BNC105 / tubulin / protein-drug complex |
Movie
Controller
Structure viewers
About Yorodumi Papers



Authors
External links










Keywords